MLYS vs TECH · $2.17B cap vs P/E 65, rev $1.22B
Mineralys Therapeutics, Inc. Common Stock (MLYS) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
MLYS does not have a complete income-statement cache yet.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
MLYS currently screens at market cap $2.17B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the MLYS and TECH stock pages for the full models.
Not investment advice.